



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(37 CFR 1.98(b))

ATTY DOCKET NO.: 249.P1C2 SERIAL NO.: 10/798,692

APPLICANT: Becker et al.

FILING DATE: 3/11/04

GROUP ART UNIT: 1654

U.S. PATENT DOCUMENTS

Examiner initials	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class/ Subclass	Filing Date
LL	5,053,215	10-01-1991	Rand et al		05-26-1988
LL	5,413,996	05-09-1995	Bodor, Nicholas		10-16-1992
LL	5,624,894	04-29-1997	Bodor, Nicholas		04-27-1995
LL	5,627,165	05-06-1997	Glazier, Arnold		09-23-1994
LL	5,663,159	09-02-1997	STARRETT JR. ET AL		10-11-1994
LL	5,792,756	08-11-1998	STARRETT JR. ET AL		06-07-1995
LL	5,798,340	08-25-1998	BISCHOFBERGER ET AL		09-16-1994
LL	5,977,061	11-02-1999	Holy et al.		04-21-1995
LL	5,977,089	11-12-1999	Arimilli et al.		11-06-1998
LL	6,169,078	01-02-2001	Hughes et al		05-12-1998
LL	6,245,750	06-12-2001	Shepard, Michael		01-22-1999
LL	6,339,151	01-15-2002	Shepard et al		01-22-1999
LL	6,348,185	02-19-2002	Piwnica-Worms, David		06-18-1999
LL	6,355,629	03-12-2002	Kozak		02-06-2001
LL	6,436,437	08-20-2002	Yatvin et al		02-15-2000
LL	US2001/0031873	10-18-2001	Greenwald et al		01-12-2001
LL	US2002/0120100A1	08-29-2002	Bonny		10-15-2001

FOREIGN PATENT DOCUMENTS

Examiner initials	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class/ Subclass	Translation Yes/No
LL	EP 0 336 364 A2	10-11-1989	NEORX CORPORATION		
LL	EP 0 481 214 A1	04-22-1992	BRISTOL-MEYERS SQUIBB COMPANY		
LL	WO 00/18775	04-06-2000			

EXAMINER

DATE CONSIDERED

5/16/2005

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(37 CFR 1.98(b))

ATTY DOCKET NO.: 249.P1C2 SERIAL NO.: 10/798,692

APPLICANT: Becker et al.

FILING DATE: 3/11/04

GROUP ART UNIT: 1654

Examiner initials	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class/ Subclass	Translation Yes/No
LL	WO 96/29336	09-26-1996	Medical Research Council		
LL	WO 96/33200	10-24-1996	Ustav Organicke Chemie A Biochemie Akademie Ved		
LL	WO 96/37503	11-28-1996	GENTA INCORPORATED		

OTHER DOCUMENTS

Examiner initials	Article
LL	Aarons et al., "Pharmacokinetic Evaluation of Site-Specific Drug Delivery Systems", 12:121-126, Novel Drug Delivery and Its Therapeutic Application (John Wiley & Sons), 1989
LL	Banerjee et al., "Design of Prodrugs Based on Enzyme-Substrate Specificity", Chapter 2, pp. 118-121, DESIGN OF PRODRUGS, 1985
LL	Brunel et al., "A Practical Method for the Large-Scale Synthesis of Diastereomerically Pure (2R,5S)-3-Phenyl-2-(8-quinolinoxy)-1,3-diaza-2-phosphabicyclo-[3.3.0]-octane Ligand (QUIPHOS)", 64:8940-8942, J ORG CHEM, 1999
LL	Bundgaard, H., "Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities", Chapter 1, pp. 70-92, DESIGN OF PRODRUGS, 1985
LL	Chapman et al., "Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340", 20(4-7):621-628, Nucleosides, Nucleotides & Nucleic Acids, 2001
LL	Connors, T.A., "Prodrugs in Cancer Chemotherapy", Chapter 9, pp. 291-316, DESIGN OF PRODRUGS, 1985
LL	Jones, Geraint, "Decreased Toxicity and Adverse Reactions via Prodrugs", Chapter 6:pp. 199-241, DESIGN OF PRODRUGS, 1985
LL	Kumar et al., "Heterocalixarenes. 1. Calix[2]uracil[2]arene: Synthesis, X-ray Structure, Conformational Analysis, and Binding Character", 64:7717-7726, J ORG CHEM, 1999
LL	McGuigan et al., "Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT", 17:311-321, ANTIVIRAL RES, 1992
LL	McGuigan et al., "Aryl Phosphate Derivatives of AZT Inhibit HIV Replication in Cells Where the Nucleoside is Poorly Active", 2(7):701-704, BIOORG MED CHEM LETT, 1992
LL	McGuigan et al., "Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase", 351:11-14, FEBS, 1994
LL	McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT", 36:1048-1052, J MED CHEM, 1993

EXAMINER

DATE CONSIDERED

5/16/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(37 CFR 1.98(b))

ATTY DOCKET NO.: 249.P1C2 SERIAL NO.: 10/798,692

APPLICANT: Becker et al.

FILING DATE: 3/11/04

GROUP ART UNIT: 1654

Examiner initials	Article
LL	McGuigan et al., "Phosphoramidates as potent prodrugs of anti-HIV nucleotides: studies in the amino region", 7(1):31-36, ANTIVIRAL CHEM & CHEMO, 1996
LL	Notari, Robert E., "Pharmacokinetic Aspects of Prodrug Design and Evaluation", Chapter 3, pp. 135-156, DESIGN OF PRODRUGS, 1985
LL	Oliyai et al., "Aryl Ester Prodrugs of Cyclic HPMPC. I: Physicochemical Characterization and In Vitro Biological Stability", 16(11):1687-1693, PHARM RES, 1999
LL	Siddiqui et al., "Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR", 42:4122-4128, PHARM RES, 1999
LL	Starrett et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)", 37:1857-1864, J MED CHEM, 1994
LL	Stella et al., "Site-Specific Drug Delivery via Prodrugs", Chapter 5, pp. 177-198, DESIGN OF PRODRUGS, 1985
LL	Stella, Valentino J., "Prodrugs and Site-Specific Drug Delivery", 23(12):1275-1282, J MED CHEM, December 1980
LL	Strube et al., "Comparison of Batch Elution and Continuous Simulated Moving Bed Chromatography", 2:305-319, ORGANIC PROCESS RESEARCH & DEVELOPMENT, 1998

EXAMINER

DATE CONSIDERED

5/16/2005

EXAMINER: Initial citation considered. Draw line-through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.